Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. META
2. NVDA
3. SPY
4. VRTX
5. LGND
6. ONON
7. USO
8. PSKY
9. MONRY
10. DGX

Go back to Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
CYTOKINETICS (NASDAQ: CYTK) Delayed: 68.67 +1.11 (1.64%)
Previous Close $67.56    52 Week High $13.18 
Open $68.07    52 Week Low $6.00 
Day High $69.56    P/E N/A 
Day Low $67.87    EPS $-1.24 
Volume 360,802